Alluvi, previously BI 4744, offers a notable development in obesity therapy. This dual agonist targeting both GLP-1 and GIP sites demonstrates impressive efficacy in research studies, potentially exceeding existing https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/